Brokerage Firm Rating on Orexigen Therapeutics (OREX)

Orexigen Therapeutics (OREX) : The consensus on Orexigen Therapeutics (OREX) based on 3 analyst recommendation on the company stock is 3.33, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst also believes that the downside risk to the stock is higher and suggests a Sell on Orexigen Therapeutics (OREX).


Company shares have received an average consensus rating of Hold for the current week Orexigen Therapeutics (NASDAQ:OREX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.14 and $4.09 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.33. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.16, notching a gain of 0.48% for the day. The total traded volume was 111,226 . The stock had closed at $4.14 on the previous day.

In a related news,The officer (Chief Commercial Officer) of Orexigen Therapeutics, Inc., Booth Mark D sold 50,000 shares at $5.68 on February 26, 2015. The Insider selling transaction had a total value worth of $284,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Companys product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Companys product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.